Fluence

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy, addictions and psychedelic therapy. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of cancer related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psilocybin-Assisted treatment of Major Depressive Disorder, a collaborator with Yale University’s study on psilocybin-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS study on treatment of Post Traumatic Stress Disorder with MDMA-Assisted Psychotherapy. Jeff is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He co-authored a paper on the influence of therapists’ first hand experience with psychedelics on psychedelic-assisted psychotherapy research in The Journal of Psychedelic Studies. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies. He maintains a private practice in New York City.